* Arbutus Biopharma Corp ABUS.OQ reported a quarterly
adjusted
loss of 11 cents per share for the quarter ended in June,
lower than the same quarter last year, when the company reported
EPS of -10 cents. The mean expectation of five analysts for the
quarter was for a loss of 10 cents per share. Wall Street
expected results to range from -11 cents to -8 cents per share.
* Revenue fell 62.9% to $1.73 million from a year ago;
analysts
expected $1.76 million.
* Arbutus Biopharma Corp's reported EPS for the quarter was
a loss
of 11 cents.
* The company reported a quarterly loss of $19.8 million.
* Arbutus Biopharma Corp shares had risen by 22.0% this
quarter and gained 50.8% so far this year.
FORECAST CHANGES
* The mean earnings estimate of analysts had risen by
about 10% in
the last three months.
* In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.
RECOMMENDATIONS
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 4 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell."
* The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"
Wall Street's median 12-month price target for Arbutus Biopharma
Corp is $4.00
This summary was machine generated from LSEG data August 1 at
01:34 p.m. UTC. All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Jun. 30 2024 -0.10 -0.11 Missed
Mar. 31 2024 -0.11 -0.10 Beat
Dec. 31 2023 -0.12 -0.12 Met
Sep. 30 2023 -0.11 -0.12 Missed